Scilex Holding
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 105
- Market Cap
- $147.5M
- Introduction
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Enhanced Safety Aesthetic Laser System
- Conditions
- HirsutismHypertrichosisTelangiectasesRhytides
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2007-07-03
- Lead Sponsor
- Scilex Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT00495443
- Locations
- 🇮🇱
Hadassah Medical Center, Dermatology, Jerusalem, Israel
Enhanced Safety Laser Hair Removal System
- Conditions
- HirsutismHypertrichosis
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- Scilex Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT00441948
- Locations
- 🇮🇱
Hadassah Medical Center, Dermatology, Jerusalem, Israel